Ventripoint Targets China’s 330M Patients with NMPA Green Channel Submission
BFLY•On April 28, Ventripoint Diagnostics’ partner submitted its VMS+ 4.0 cardiac AI system to China’s NMPA green channel, targeting access to 330 million cardiovascular patients. Concurrently the company exhibited at AEPC in Padua and secured an Edison Award, Northern California hospital deal and Nisg̱a'a partnership.
1. Regulatory Submission to China's NMPA
On April 28, Ventripoint’s strategic partner Lishman Global filed the VMS+ 4.0 system with China’s National Medical Products Administration via the expedited green channel pathway. This submission aims to unlock access to an estimated 330 million cardiovascular disease patients by demonstrating innovative AI-driven volumetric measurements on existing ultrasound platforms.
2. AEPC Exhibition Highlights European Push
Between May 12–16 in Padua, Ventripoint showcased VMS+ 4.0 at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology. The booth emphasized fast, MRI-equivalent cardiac assessments tailored to congenital heart disease guidelines and point-of-care workflows, targeting over 1,000 specialists from 32 countries.
3. Commercial Partnerships and Industry Recognition
Since early 2026, Ventripoint has built a validation chain including an Edison Award, a commercial agreement with LG Consulting Solutions for Northern California hospitals, and a Nisg̱a'a partnership to deliver AI 3D heart mapping in Indigenous community settings. These developments reinforce its multi-front strategy across regulatory, commercial and reimbursement channels.
